JP2020533296A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533296A5 JP2020533296A5 JP2020513603A JP2020513603A JP2020533296A5 JP 2020533296 A5 JP2020533296 A5 JP 2020533296A5 JP 2020513603 A JP2020513603 A JP 2020513603A JP 2020513603 A JP2020513603 A JP 2020513603A JP 2020533296 A5 JP2020533296 A5 JP 2020533296A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- predopidine
- levodopa
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 9
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 9
- 229960004502 levodopa Drugs 0.000 claims 9
- 208000012661 Dyskinesia Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000012639 Balance disease Diseases 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000005622 Gait Ataxia Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000012601 choreatic disease Diseases 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 230000001788 irregular Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556314P | 2017-09-08 | 2017-09-08 | |
| US62/556,314 | 2017-09-08 | ||
| US201862649184P | 2018-03-28 | 2018-03-28 | |
| US62/649,184 | 2018-03-28 | ||
| PCT/US2018/048920 WO2019050775A1 (en) | 2017-09-08 | 2018-08-30 | PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020533296A JP2020533296A (ja) | 2020-11-19 |
| JP2020533296A5 true JP2020533296A5 (enExample) | 2021-03-04 |
Family
ID=63684481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513603A Pending JP2020533296A (ja) | 2017-09-08 | 2018-08-30 | 薬物誘発性ジスキネジアを治療するためのプリドピジン |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190231768A1 (enExample) |
| EP (1) | EP3678664A1 (enExample) |
| JP (1) | JP2020533296A (enExample) |
| CN (1) | CN111343982A (enExample) |
| AU (1) | AU2018329628B2 (enExample) |
| BR (1) | BR112020004622A2 (enExample) |
| CA (1) | CA3075020C (enExample) |
| IL (1) | IL273044A (enExample) |
| MX (1) | MX383462B (enExample) |
| WO (1) | WO2019050775A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CN110012661A (zh) | 2016-08-24 | 2019-07-12 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗肌张力障碍的用途 |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| JP7585561B2 (ja) | 2019-02-04 | 2024-11-19 | プリレニア ニューロセラピューティクス リミテッド | パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン |
| AU2020243692B2 (en) | 2019-03-15 | 2023-03-02 | Prilenia Neurotherapeutics Ltd. | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
| CN116472043A (zh) | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
| CA3214354A1 (en) * | 2021-04-14 | 2022-10-20 | Michael Hayden | Treatment of prodromal huntington disease |
| KR102906269B1 (ko) | 2023-08-03 | 2026-01-02 | 재단법인대구경북과학기술원 | 파킨슨 환자의 lid 발병 예측을 위한 정보제공방법 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| ES2659577T3 (es) | 2004-10-13 | 2018-03-16 | Teva Pharmaceuticals International Gmbh | Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina |
| SE529246C2 (sv) * | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| MX2009011020A (es) | 2007-04-12 | 2009-10-30 | Nsab Af Neurosearch Sweden Ab | Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. |
| US20100197712A1 (en) | 2007-06-18 | 2010-08-05 | Arvid Carlsson | Use of dopamine stabilizers |
| US20110206782A1 (en) | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| CN103080343A (zh) | 2010-07-02 | 2013-05-01 | Skf公司 | 机械部件和用于表面硬化的方法 |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| MX343620B (es) | 2011-09-07 | 2016-11-11 | Teva Pharmaceuticals Int Gmbh | Forma polimorfica de clorhidrato de pridopidina. |
| EP2787997A4 (en) * | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| BR112014024672A8 (pt) | 2012-04-04 | 2018-04-03 | Ivax Int Gmbh | Composições farmacêuticas para terapia de combinação |
| CA2913781C (en) | 2013-06-21 | 2022-05-10 | Teva Pharmaceutical Industries Ltd. | Use of pridopidine for treating huntington's disease |
| DK177976B8 (en) | 2013-07-10 | 2021-04-22 | Jasopels As | Apparatus and method for stretching a pelt on a pelt board |
| CA2937243C (en) | 2014-01-22 | 2023-07-18 | Teva Pharmaceuticals International Gmbh | Modified release formulations of pridopidine |
| CN106062752B (zh) | 2014-03-10 | 2020-03-17 | 应用材料公司 | 用于多带电粒子束平板印刷术的像素融合 |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| EP3854785A1 (en) | 2015-02-25 | 2021-07-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| EP3324967A4 (en) | 2015-07-22 | 2019-03-20 | Prilenia Therapeutics Development Ltd. | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME |
| EP3419622B1 (en) | 2016-02-24 | 2024-03-06 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| CN110012661A (zh) | 2016-08-24 | 2019-07-12 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗肌张力障碍的用途 |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| AU2017326436A1 (en) | 2016-09-15 | 2019-04-11 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for the treatment of anxiety and depression |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
| ES2972205T3 (es) | 2017-01-20 | 2024-06-11 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento del síndrome x frágil |
| HUE061505T2 (hu) | 2017-08-14 | 2023-07-28 | Prilenia Neurotherapeutics Ltd | Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel |
| JP2020532517A (ja) * | 2017-08-30 | 2020-11-12 | プリレニア ニューロセラピューティクス リミテッド | 高濃度プリドピジン製剤 |
| DE102018204527A1 (de) | 2017-09-18 | 2019-03-21 | SEs Solutions GmbH | Dachhalterung für ein Automobil |
-
2018
- 2018-08-30 CA CA3075020A patent/CA3075020C/en active Active
- 2018-08-30 MX MX2020002645A patent/MX383462B/es unknown
- 2018-08-30 CN CN201880072818.0A patent/CN111343982A/zh active Pending
- 2018-08-30 AU AU2018329628A patent/AU2018329628B2/en active Active
- 2018-08-30 BR BR112020004622-1A patent/BR112020004622A2/pt not_active IP Right Cessation
- 2018-08-30 JP JP2020513603A patent/JP2020533296A/ja active Pending
- 2018-08-30 EP EP18778648.8A patent/EP3678664A1/en active Pending
- 2018-08-30 WO PCT/US2018/048920 patent/WO2019050775A1/en not_active Ceased
-
2019
- 2019-04-08 US US16/377,577 patent/US20190231768A1/en not_active Abandoned
- 2019-06-11 US US16/436,947 patent/US11000519B2/en active Active
-
2020
- 2020-03-03 IL IL273044A patent/IL273044A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI2629097T1 (fi) | Nrf2-seulontatestejä ja niihin liittyviä menetelmiä ja koostumuksia | |
| JP2010518122A5 (enExample) | ||
| RU2018133298A (ru) | Способы применения агонистов fxr | |
| JP2019515884A5 (enExample) | ||
| JP2013529665A5 (enExample) | ||
| JP2018500300A (ja) | パーキンソン病を遅延させるための医薬 | |
| KR20160111013A (ko) | 신경질환의 치료를 위한 바클로펜, 아캄프로세이트 및 중쇄 트리-글리세리드의 조합 | |
| RU2004132856A (ru) | Фармацевтический препарат с модифицированным высвобождением | |
| JP2022554276A5 (enExample) | ||
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| JP2019218379A5 (enExample) | ||
| JP2020522560A5 (enExample) | ||
| JP2022514537A5 (enExample) | ||
| RU2017127509A (ru) | Композиции и способы для улучшенного мышечного метаболизма | |
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use | |
| EP2968227B1 (en) | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis | |
| JP2020509072A5 (enExample) | ||
| JP2016528171A5 (enExample) | ||
| JP2020531543A5 (enExample) | ||
| JP2019085364A5 (enExample) | ||
| JP2022512158A5 (enExample) | ||
| JP2018505901A5 (enExample) | ||
| TWI833874B (zh) | 神經變性疾病之預防或治療藥 | |
| WO2016073716A1 (en) | Methods of treating huntington's disease using cysteamine compositions | |
| JP2019535830A5 (enExample) |